treatment group:Sintilimab

3 trials

Sponsors

Cancer Center of Sun Yat-Sen University, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences

Conditions

Squamous cell carcinoma of head and neckesophageal cancerrenal cell carcinoma

Early Phase 1

A prospective, single-arm, single-center, phase II pilot study of sintilimab (IBI308) combined with chemotherapy as induction therapy for locally advanced head and neck squamous cell carcinoma

RecruitingChiCTR2200061313

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical SciencesSquamous cell carcinoma of head and neck

Start: 2021-12-30Updated: 2023-04-03

A single-arm, Phase II exploratory clinical study of Sintilimab in combination with albumin-paclitaxel and nedaplatin for neoadjuvant treatment of esophageal cancer

RecruitingChiCTR2400086739

Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciencesesophageal cancer

Start: 2022-04-02Updated: 2024-07-15

Phase 2

Efficacy and safety of axitinib combined with PD1 inhibitor neoadjuvant treatment of locally advanced renal cell carcinoma: a single center single arm phase II clinical study

RecruitingChiCTR2000039666

Cancer Center of Sun Yat-Sen Universityrenal cell carcinoma

Start: 2020-12-01Updated: 2021-02-08